Pharma & Healthcare

Global Tumor Immunity Therapy Market Research Report 2025

The global market for Tumor Immunity Therapy was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for Tumor Immunity Therapy is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Tumor Immunity Therapy is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Tumor Immunity Therapy in Hospital is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Tumor Immunity Therapy include Bristol-Myers Squibb, Merck & Co., Inc., Roche AG, AstraZeneca, Plc, Sanofi S.A., Dendreon Pharmaceuticals, Novartis, Gilead Sciences Inc., IMVAQ Therapeutics, Arch Oncology, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Tumor Immunity Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tumor Immunity Therapy.
The Tumor Immunity Therapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Tumor Immunity Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Tumor Immunity Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bristol-Myers Squibb
Merck & Co., Inc.
Roche AG
AstraZeneca, Plc
Sanofi S.A.
Dendreon Pharmaceuticals
Novartis
Gilead Sciences Inc.
IMVAQ Therapeutics
Arch Oncology
Juno Therapeutics
Refuge
Lepu Biopharma
Genoimmune
TCR Cure
Segment by Type
Immune Checkpoint Inhibitor
Cytokine Immunotherapy
Cancer Vaccine
Car-t Cell Therapy
Others
Segment by Application
Hospital
Clinic
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Tumor Immunity Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Tumor Immunity Therapy Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Immune Checkpoint Inhibitor
1.2.3 Cytokine Immunotherapy
1.2.4 Cancer Vaccine
1.2.5 Car-t Cell Therapy
1.2.6 Others
1.3 Market by Application
1.3.1 Global Tumor Immunity Therapy Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Tumor Immunity Therapy Market Perspective (2020-2031)
2.2 Global Tumor Immunity Therapy Growth Trends by Region
2.2.1 Global Tumor Immunity Therapy Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Tumor Immunity Therapy Historic Market Size by Region (2020-2025)
2.2.3 Tumor Immunity Therapy Forecasted Market Size by Region (2026-2031)
2.3 Tumor Immunity Therapy Market Dynamics
2.3.1 Tumor Immunity Therapy Industry Trends
2.3.2 Tumor Immunity Therapy Market Drivers
2.3.3 Tumor Immunity Therapy Market Challenges
2.3.4 Tumor Immunity Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Tumor Immunity Therapy Players by Revenue
3.1.1 Global Top Tumor Immunity Therapy Players by Revenue (2020-2025)
3.1.2 Global Tumor Immunity Therapy Revenue Market Share by Players (2020-2025)
3.2 Global Tumor Immunity Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Tumor Immunity Therapy Revenue
3.4 Global Tumor Immunity Therapy Market Concentration Ratio
3.4.1 Global Tumor Immunity Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Tumor Immunity Therapy Revenue in 2024
3.5 Global Key Players of Tumor Immunity Therapy Head office and Area Served
3.6 Global Key Players of Tumor Immunity Therapy, Product and Application
3.7 Global Key Players of Tumor Immunity Therapy, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Tumor Immunity Therapy Breakdown Data by Type
4.1 Global Tumor Immunity Therapy Historic Market Size by Type (2020-2025)
4.2 Global Tumor Immunity Therapy Forecasted Market Size by Type (2026-2031)
5 Tumor Immunity Therapy Breakdown Data by Application
5.1 Global Tumor Immunity Therapy Historic Market Size by Application (2020-2025)
5.2 Global Tumor Immunity Therapy Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Tumor Immunity Therapy Market Size (2020-2031)
6.2 North America Tumor Immunity Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Tumor Immunity Therapy Market Size by Country (2020-2025)
6.4 North America Tumor Immunity Therapy Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Tumor Immunity Therapy Market Size (2020-2031)
7.2 Europe Tumor Immunity Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Tumor Immunity Therapy Market Size by Country (2020-2025)
7.4 Europe Tumor Immunity Therapy Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Tumor Immunity Therapy Market Size (2020-2031)
8.2 Asia-Pacific Tumor Immunity Therapy Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Tumor Immunity Therapy Market Size by Region (2020-2025)
8.4 Asia-Pacific Tumor Immunity Therapy Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Tumor Immunity Therapy Market Size (2020-2031)
9.2 Latin America Tumor Immunity Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Tumor Immunity Therapy Market Size by Country (2020-2025)
9.4 Latin America Tumor Immunity Therapy Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Tumor Immunity Therapy Market Size (2020-2031)
10.2 Middle East & Africa Tumor Immunity Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Tumor Immunity Therapy Market Size by Country (2020-2025)
10.4 Middle East & Africa Tumor Immunity Therapy Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Details
11.1.2 Bristol-Myers Squibb Business Overview
11.1.3 Bristol-Myers Squibb Tumor Immunity Therapy Introduction
11.1.4 Bristol-Myers Squibb Revenue in Tumor Immunity Therapy Business (2020-2025)
11.1.5 Bristol-Myers Squibb Recent Development
11.2 Merck & Co., Inc.
11.2.1 Merck & Co., Inc. Company Details
11.2.2 Merck & Co., Inc. Business Overview
11.2.3 Merck & Co., Inc. Tumor Immunity Therapy Introduction
11.2.4 Merck & Co., Inc. Revenue in Tumor Immunity Therapy Business (2020-2025)
11.2.5 Merck & Co., Inc. Recent Development
11.3 Roche AG
11.3.1 Roche AG Company Details
11.3.2 Roche AG Business Overview
11.3.3 Roche AG Tumor Immunity Therapy Introduction
11.3.4 Roche AG Revenue in Tumor Immunity Therapy Business (2020-2025)
11.3.5 Roche AG Recent Development
11.4 AstraZeneca, Plc
11.4.1 AstraZeneca, Plc Company Details
11.4.2 AstraZeneca, Plc Business Overview
11.4.3 AstraZeneca, Plc Tumor Immunity Therapy Introduction
11.4.4 AstraZeneca, Plc Revenue in Tumor Immunity Therapy Business (2020-2025)
11.4.5 AstraZeneca, Plc Recent Development
11.5 Sanofi S.A.
11.5.1 Sanofi S.A. Company Details
11.5.2 Sanofi S.A. Business Overview
11.5.3 Sanofi S.A. Tumor Immunity Therapy Introduction
11.5.4 Sanofi S.A. Revenue in Tumor Immunity Therapy Business (2020-2025)
11.5.5 Sanofi S.A. Recent Development
11.6 Dendreon Pharmaceuticals
11.6.1 Dendreon Pharmaceuticals Company Details
11.6.2 Dendreon Pharmaceuticals Business Overview
11.6.3 Dendreon Pharmaceuticals Tumor Immunity Therapy Introduction
11.6.4 Dendreon Pharmaceuticals Revenue in Tumor Immunity Therapy Business (2020-2025)
11.6.5 Dendreon Pharmaceuticals Recent Development
11.7 Novartis
11.7.1 Novartis Company Details
11.7.2 Novartis Business Overview
11.7.3 Novartis Tumor Immunity Therapy Introduction
11.7.4 Novartis Revenue in Tumor Immunity Therapy Business (2020-2025)
11.7.5 Novartis Recent Development
11.8 Gilead Sciences Inc.
11.8.1 Gilead Sciences Inc. Company Details
11.8.2 Gilead Sciences Inc. Business Overview
11.8.3 Gilead Sciences Inc. Tumor Immunity Therapy Introduction
11.8.4 Gilead Sciences Inc. Revenue in Tumor Immunity Therapy Business (2020-2025)
11.8.5 Gilead Sciences Inc. Recent Development
11.9 IMVAQ Therapeutics
11.9.1 IMVAQ Therapeutics Company Details
11.9.2 IMVAQ Therapeutics Business Overview
11.9.3 IMVAQ Therapeutics Tumor Immunity Therapy Introduction
11.9.4 IMVAQ Therapeutics Revenue in Tumor Immunity Therapy Business (2020-2025)
11.9.5 IMVAQ Therapeutics Recent Development
11.10 Arch Oncology
11.10.1 Arch Oncology Company Details
11.10.2 Arch Oncology Business Overview
11.10.3 Arch Oncology Tumor Immunity Therapy Introduction
11.10.4 Arch Oncology Revenue in Tumor Immunity Therapy Business (2020-2025)
11.10.5 Arch Oncology Recent Development
11.11 Juno Therapeutics
11.11.1 Juno Therapeutics Company Details
11.11.2 Juno Therapeutics Business Overview
11.11.3 Juno Therapeutics Tumor Immunity Therapy Introduction
11.11.4 Juno Therapeutics Revenue in Tumor Immunity Therapy Business (2020-2025)
11.11.5 Juno Therapeutics Recent Development
11.12 Refuge
11.12.1 Refuge Company Details
11.12.2 Refuge Business Overview
11.12.3 Refuge Tumor Immunity Therapy Introduction
11.12.4 Refuge Revenue in Tumor Immunity Therapy Business (2020-2025)
11.12.5 Refuge Recent Development
11.13 Lepu Biopharma
11.13.1 Lepu Biopharma Company Details
11.13.2 Lepu Biopharma Business Overview
11.13.3 Lepu Biopharma Tumor Immunity Therapy Introduction
11.13.4 Lepu Biopharma Revenue in Tumor Immunity Therapy Business (2020-2025)
11.13.5 Lepu Biopharma Recent Development
11.14 Genoimmune
11.14.1 Genoimmune Company Details
11.14.2 Genoimmune Business Overview
11.14.3 Genoimmune Tumor Immunity Therapy Introduction
11.14.4 Genoimmune Revenue in Tumor Immunity Therapy Business (2020-2025)
11.14.5 Genoimmune Recent Development
11.15 TCR Cure
11.15.1 TCR Cure Company Details
11.15.2 TCR Cure Business Overview
11.15.3 TCR Cure Tumor Immunity Therapy Introduction
11.15.4 TCR Cure Revenue in Tumor Immunity Therapy Business (2020-2025)
11.15.5 TCR Cure Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Tumor Immunity Therapy Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Immune Checkpoint Inhibitor
Table 3. Key Players of Cytokine Immunotherapy
Table 4. Key Players of Cancer Vaccine
Table 5. Key Players of Car-t Cell Therapy
Table 6. Key Players of Others
Table 7. Global Tumor Immunity Therapy Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Tumor Immunity Therapy Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Tumor Immunity Therapy Market Size by Region (2020-2025) & (US$ Million)
Table 10. Global Tumor Immunity Therapy Market Share by Region (2020-2025)
Table 11. Global Tumor Immunity Therapy Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 12. Global Tumor Immunity Therapy Market Share by Region (2026-2031)
Table 13. Tumor Immunity Therapy Market Trends
Table 14. Tumor Immunity Therapy Market Drivers
Table 15. Tumor Immunity Therapy Market Challenges
Table 16. Tumor Immunity Therapy Market Restraints
Table 17. Global Tumor Immunity Therapy Revenue by Players (2020-2025) & (US$ Million)
Table 18. Global Tumor Immunity Therapy Market Share by Players (2020-2025)
Table 19. Global Top Tumor Immunity Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumor Immunity Therapy as of 2024)
Table 20. Ranking of Global Top Tumor Immunity Therapy Companies by Revenue (US$ Million) in 2024
Table 21. Global 5 Largest Players Market Share by Tumor Immunity Therapy Revenue (CR5 and HHI) & (2020-2025)
Table 22. Global Key Players of Tumor Immunity Therapy, Headquarters and Area Served
Table 23. Global Key Players of Tumor Immunity Therapy, Product and Application
Table 24. Global Key Players of Tumor Immunity Therapy, Date of Enter into This Industry
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Tumor Immunity Therapy Market Size by Type (2020-2025) & (US$ Million)
Table 27. Global Tumor Immunity Therapy Revenue Market Share by Type (2020-2025)
Table 28. Global Tumor Immunity Therapy Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 29. Global Tumor Immunity Therapy Revenue Market Share by Type (2026-2031)
Table 30. Global Tumor Immunity Therapy Market Size by Application (2020-2025) & (US$ Million)
Table 31. Global Tumor Immunity Therapy Revenue Market Share by Application (2020-2025)
Table 32. Global Tumor Immunity Therapy Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 33. Global Tumor Immunity Therapy Revenue Market Share by Application (2026-2031)
Table 34. North America Tumor Immunity Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. North America Tumor Immunity Therapy Market Size by Country (2020-2025) & (US$ Million)
Table 36. North America Tumor Immunity Therapy Market Size by Country (2026-2031) & (US$ Million)
Table 37. Europe Tumor Immunity Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 38. Europe Tumor Immunity Therapy Market Size by Country (2020-2025) & (US$ Million)
Table 39. Europe Tumor Immunity Therapy Market Size by Country (2026-2031) & (US$ Million)
Table 40. Asia-Pacific Tumor Immunity Therapy Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 41. Asia-Pacific Tumor Immunity Therapy Market Size by Region (2020-2025) & (US$ Million)
Table 42. Asia-Pacific Tumor Immunity Therapy Market Size by Region (2026-2031) & (US$ Million)
Table 43. Latin America Tumor Immunity Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Latin America Tumor Immunity Therapy Market Size by Country (2020-2025) & (US$ Million)
Table 45. Latin America Tumor Immunity Therapy Market Size by Country (2026-2031) & (US$ Million)
Table 46. Middle East & Africa Tumor Immunity Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 47. Middle East & Africa Tumor Immunity Therapy Market Size by Country (2020-2025) & (US$ Million)
Table 48. Middle East & Africa Tumor Immunity Therapy Market Size by Country (2026-2031) & (US$ Million)
Table 49. Bristol-Myers Squibb Company Details
Table 50. Bristol-Myers Squibb Business Overview
Table 51. Bristol-Myers Squibb Tumor Immunity Therapy Product
Table 52. Bristol-Myers Squibb Revenue in Tumor Immunity Therapy Business (2020-2025) & (US$ Million)
Table 53. Bristol-Myers Squibb Recent Development
Table 54. Merck & Co., Inc. Company Details
Table 55. Merck & Co., Inc. Business Overview
Table 56. Merck & Co., Inc. Tumor Immunity Therapy Product
Table 57. Merck & Co., Inc. Revenue in Tumor Immunity Therapy Business (2020-2025) & (US$ Million)
Table 58. Merck & Co., Inc. Recent Development
Table 59. Roche AG Company Details
Table 60. Roche AG Business Overview
Table 61. Roche AG Tumor Immunity Therapy Product
Table 62. Roche AG Revenue in Tumor Immunity Therapy Business (2020-2025) & (US$ Million)
Table 63. Roche AG Recent Development
Table 64. AstraZeneca, Plc Company Details
Table 65. AstraZeneca, Plc Business Overview
Table 66. AstraZeneca, Plc Tumor Immunity Therapy Product
Table 67. AstraZeneca, Plc Revenue in Tumor Immunity Therapy Business (2020-2025) & (US$ Million)
Table 68. AstraZeneca, Plc Recent Development
Table 69. Sanofi S.A. Company Details
Table 70. Sanofi S.A. Business Overview
Table 71. Sanofi S.A. Tumor Immunity Therapy Product
Table 72. Sanofi S.A. Revenue in Tumor Immunity Therapy Business (2020-2025) & (US$ Million)
Table 73. Sanofi S.A. Recent Development
Table 74. Dendreon Pharmaceuticals Company Details
Table 75. Dendreon Pharmaceuticals Business Overview
Table 76. Dendreon Pharmaceuticals Tumor Immunity Therapy Product
Table 77. Dendreon Pharmaceuticals Revenue in Tumor Immunity Therapy Business (2020-2025) & (US$ Million)
Table 78. Dendreon Pharmaceuticals Recent Development
Table 79. Novartis Company Details
Table 80. Novartis Business Overview
Table 81. Novartis Tumor Immunity Therapy Product
Table 82. Novartis Revenue in Tumor Immunity Therapy Business (2020-2025) & (US$ Million)
Table 83. Novartis Recent Development
Table 84. Gilead Sciences Inc. Company Details
Table 85. Gilead Sciences Inc. Business Overview
Table 86. Gilead Sciences Inc. Tumor Immunity Therapy Product
Table 87. Gilead Sciences Inc. Revenue in Tumor Immunity Therapy Business (2020-2025) & (US$ Million)
Table 88. Gilead Sciences Inc. Recent Development
Table 89. IMVAQ Therapeutics Company Details
Table 90. IMVAQ Therapeutics Business Overview
Table 91. IMVAQ Therapeutics Tumor Immunity Therapy Product
Table 92. IMVAQ Therapeutics Revenue in Tumor Immunity Therapy Business (2020-2025) & (US$ Million)
Table 93. IMVAQ Therapeutics Recent Development
Table 94. Arch Oncology Company Details
Table 95. Arch Oncology Business Overview
Table 96. Arch Oncology Tumor Immunity Therapy Product
Table 97. Arch Oncology Revenue in Tumor Immunity Therapy Business (2020-2025) & (US$ Million)
Table 98. Arch Oncology Recent Development
Table 99. Juno Therapeutics Company Details
Table 100. Juno Therapeutics Business Overview
Table 101. Juno Therapeutics Tumor Immunity Therapy Product
Table 102. Juno Therapeutics Revenue in Tumor Immunity Therapy Business (2020-2025) & (US$ Million)
Table 103. Juno Therapeutics Recent Development
Table 104. Refuge Company Details
Table 105. Refuge Business Overview
Table 106. Refuge Tumor Immunity Therapy Product
Table 107. Refuge Revenue in Tumor Immunity Therapy Business (2020-2025) & (US$ Million)
Table 108. Refuge Recent Development
Table 109. Lepu Biopharma Company Details
Table 110. Lepu Biopharma Business Overview
Table 111. Lepu Biopharma Tumor Immunity Therapy Product
Table 112. Lepu Biopharma Revenue in Tumor Immunity Therapy Business (2020-2025) & (US$ Million)
Table 113. Lepu Biopharma Recent Development
Table 114. Genoimmune Company Details
Table 115. Genoimmune Business Overview
Table 116. Genoimmune Tumor Immunity Therapy Product
Table 117. Genoimmune Revenue in Tumor Immunity Therapy Business (2020-2025) & (US$ Million)
Table 118. Genoimmune Recent Development
Table 119. TCR Cure Company Details
Table 120. TCR Cure Business Overview
Table 121. TCR Cure Tumor Immunity Therapy Product
Table 122. TCR Cure Revenue in Tumor Immunity Therapy Business (2020-2025) & (US$ Million)
Table 123. TCR Cure Recent Development
Table 124. Research Programs/Design for This Report
Table 125. Key Data Information from Secondary Sources
Table 126. Key Data Information from Primary Sources
Table 127. Authors List of This Report


List of Figures
Figure 1. Tumor Immunity Therapy Picture
Figure 2. Global Tumor Immunity Therapy Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Tumor Immunity Therapy Market Share by Type: 2024 VS 2031
Figure 4. Immune Checkpoint Inhibitor Features
Figure 5. Cytokine Immunotherapy Features
Figure 6. Cancer Vaccine Features
Figure 7. Car-t Cell Therapy Features
Figure 8. Others Features
Figure 9. Global Tumor Immunity Therapy Market Size by Application (2020-2031) & (US$ Million)
Figure 10. Global Tumor Immunity Therapy Market Share by Application: 2024 VS 2031
Figure 11. Hospital Case Studies
Figure 12. Clinic Case Studies
Figure 13. Tumor Immunity Therapy Report Years Considered
Figure 14. Global Tumor Immunity Therapy Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global Tumor Immunity Therapy Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Tumor Immunity Therapy Market Share by Region: 2024 VS 2031
Figure 17. Global Tumor Immunity Therapy Market Share by Players in 2024
Figure 18. Global Top Tumor Immunity Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumor Immunity Therapy as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Tumor Immunity Therapy Revenue in 2024
Figure 20. North America Tumor Immunity Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America Tumor Immunity Therapy Market Share by Country (2020-2031)
Figure 22. United States Tumor Immunity Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada Tumor Immunity Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Tumor Immunity Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Tumor Immunity Therapy Market Share by Country (2020-2031)
Figure 26. Germany Tumor Immunity Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France Tumor Immunity Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. Tumor Immunity Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy Tumor Immunity Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia Tumor Immunity Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries Tumor Immunity Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Tumor Immunity Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Tumor Immunity Therapy Market Share by Region (2020-2031)
Figure 34. China Tumor Immunity Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan Tumor Immunity Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea Tumor Immunity Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia Tumor Immunity Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India Tumor Immunity Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia Tumor Immunity Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Tumor Immunity Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Tumor Immunity Therapy Market Share by Country (2020-2031)
Figure 42. Mexico Tumor Immunity Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil Tumor Immunity Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Tumor Immunity Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Tumor Immunity Therapy Market Share by Country (2020-2031)
Figure 46. Turkey Tumor Immunity Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia Tumor Immunity Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE Tumor Immunity Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Bristol-Myers Squibb Revenue Growth Rate in Tumor Immunity Therapy Business (2020-2025)
Figure 50. Merck & Co., Inc. Revenue Growth Rate in Tumor Immunity Therapy Business (2020-2025)
Figure 51. Roche AG Revenue Growth Rate in Tumor Immunity Therapy Business (2020-2025)
Figure 52. AstraZeneca, Plc Revenue Growth Rate in Tumor Immunity Therapy Business (2020-2025)
Figure 53. Sanofi S.A. Revenue Growth Rate in Tumor Immunity Therapy Business (2020-2025)
Figure 54. Dendreon Pharmaceuticals Revenue Growth Rate in Tumor Immunity Therapy Business (2020-2025)
Figure 55. Novartis Revenue Growth Rate in Tumor Immunity Therapy Business (2020-2025)
Figure 56. Gilead Sciences Inc. Revenue Growth Rate in Tumor Immunity Therapy Business (2020-2025)
Figure 57. IMVAQ Therapeutics Revenue Growth Rate in Tumor Immunity Therapy Business (2020-2025)
Figure 58. Arch Oncology Revenue Growth Rate in Tumor Immunity Therapy Business (2020-2025)
Figure 59. Juno Therapeutics Revenue Growth Rate in Tumor Immunity Therapy Business (2020-2025)
Figure 60. Refuge Revenue Growth Rate in Tumor Immunity Therapy Business (2020-2025)
Figure 61. Lepu Biopharma Revenue Growth Rate in Tumor Immunity Therapy Business (2020-2025)
Figure 62. Genoimmune Revenue Growth Rate in Tumor Immunity Therapy Business (2020-2025)
Figure 63. TCR Cure Revenue Growth Rate in Tumor Immunity Therapy Business (2020-2025)
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies